Vectivbio Holding Ag Stock Price, News & Analysis

VectivBio Holding AG, a clinical-stage biopharmaceutical company, announced that its CEO, Luca Santarelli, will present at the Jefferies London Healthcare Conference on November 17, 2022, at 8:35 a.m. GMT. The conference aims to discuss their innovations in treatments for severe rare conditions, including the lead product candidate, apraglutide, designed for gastrointestinal diseases. A live webcast will be available, and recordings can be accessed on their website.

VectivBio has completed patient enrollment for the Colon-in-Continuity (CIC) cohort in its Phase 3 STARS study, evaluating the safety and efficacy of apraglutide for Short Bowel Syndrome with Intestinal Failure (SBS-IF).

The study, the largest of its kind, includes 144 patients and aims to establish a new standard of care, with top-line results expected by the end of 2023.

The findings could support a differentiated label claim for apraglutide and enhance treatment options for SBS-IF patients based on their bowel anatomy.

VectivBio Holding AG (Nasdaq: VECT) has successfully closed an underwritten offering of 16,700,000 ordinary shares at $7.50 per share, generating approximately $125 million in gross proceeds. Key investors included notable names such as Cowen Healthcare Investments and Eventide Asset Management. The funds will support clinical development and pre-commercialization activities for its lead product candidate and cover general corporate purposes. Jefferies, SVB Securities, and Piper Sandler acted as joint book-running managers for this offering.

VectivBio Holding AG (Nasdaq: VECT) announced a $125 million underwritten offering of 16,700,000 ordinary shares priced at $7.50 per share. Key investors include Cowen Healthcare and OrbiMed, among others. The proceeds will support clinical development for the lead product candidate, apraglutide, and fund general corporate purposes. The offering is set to close around October 17, 2022, subject to customary conditions. Jefferies, SVB Securities, and Piper Sandler are the joint book-running managers for this offering.

VectivBio announced promising interim results from its Phase 2 STARS Nutrition study on apraglutide, a GLP-2 agonist for Short Bowel Syndrome with Intestinal Failure (SBS-IF) patients, specifically those with Colon-in-Continuity (CIC). The study showed an average 50% reduction in parenteral support volume at six months, with 80% of patients responding clinically. This research is the first to demonstrate the efficacy of apraglutide in CIC patients, highlighting a significant unmet medical need. Top-line data for all patients is expected soon.

VectivBio Holding AG (Nasdaq: VECT) announced the date for its Extraordinary General Meeting on December 9, 2022, at 10:00 a.m. CEST in Basel, Switzerland. The meeting will focus solely on the election of Wouter Joustra to the Board of Directors. Due to COVID-19, shareholders will not be allowed to attend in person and must use an independent proxy for representation. VectivBio specializes in treatments for severe rare conditions, with its lead candidate apraglutide addressing gastrointestinal diseases.

VectivBio Holding AG has successfully completed a public offering of 6,467,688 ordinary shares at $5.25 per share, generating approximately $34 million. Additionally, a private placement of 3,478,260 shares was executed at $5.75 per share, totaling gross proceeds of around $20 million. The public offering involved underwriters SVB Securities and Piper Sandler, with LifeSci Capital acting as co-manager. Forbion’s Growth Opportunities Fund II participated in the private placement, with potential board member nomination rights. Both offerings are aimed at supporting VectivBio's clinical-stage development of treatments for severe rare conditions.

VectivBio Announces $50 Million Offering

On June 14, 2022, VectivBio (Nasdaq: VECT) priced a public offering of 5,715,000 shares at $5.25 per share, aiming for gross proceeds of $30 million. Additionally, a private placement to Forbion will raise approximately $20 million by selling 3,478,260 shares at $5.75 each. The total gross proceeds from both offerings amount to $50 million. Funds will support clinical development and general corporate activities. The public offering is expected to close around June 17, 2022, pending customary conditions.

VectivBio Holding AG (Nasdaq: VECT) announced a follow-on public offering of its ordinary shares, along with a private placement of 3,478,260 shares to Forbion at $5.75 each, expected to raise around $20 million. The proceeds will fund clinical development of its lead candidate, apraglutide, targeting severe rare conditions, and general corporate purposes. The offering hinges on market conditions and will not be registered under the Securities Act. SVB Securities and Piper Sandler are managing the public offering.